Yamin Khan

Pharm-Olam International started operations in 1994 with the premise of delivering cost effective, quick-to-market clinical services in the emerging markets of Central and Eastern Europe. Since then, POI has expanded its services to more than 40 countries, including: North America, Western Europe, Central & Eastern Europe, Latin America, India, and South Africa. Today, POI has one of the largest global footprints of any CRO. They are committed to establishing and maintaining the industry's strongest multi-national presence. Its monitors have the most extensive knowledge of local and regional customs and sites across a broad range of therapeutic areas. POI has an entirely different model than other CROs- they call it global decentralization. The success of this model has been proven time and again.

Part of Shomer XV Ltd., Pharm-Olam International (UK) Ltd. is a clinical research organization that specializes in solving distinct challenges of small and mid-sized biopharma companies. The private company is based in Bracknell, UK and operates under the name allucent. The British company offers contract research services and clinical expertise to ensure the success of their clients' products. The company's resource center provides the latest articles, blogs, brochures, and videos from their experts.